Extranodal NK-T-cell lymphoma medical therapy: Difference between revisions

	Extranodal NK-T-cell lymphoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Extranodal NK-T-cell lymphoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Staging
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Xray
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Extranodal NK-T-cell lymphoma medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Extranodal NK-T-cell lymphoma medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Extranodal NK-T-cell lymphoma medical therapy
CDC on Extranodal NK-T-cell lymphoma medical therapy
Extranodal NK-T-cell lymphoma medical therapy in the news
Blogs on Extranodal NK-T-cell lymphoma medical therapy
Risk calculators and risk factors for Extranodal NK-T-cell lymphoma medical therapy

← Older edit

VisualWikitext

Latest revision as of 14:35, 30 August 2019

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ramyar Ghandriz MD [2]

Overview

The predominant therapy for extranodal NK-T-cell lymphoma is radiation therapy. Adjudicative chemotherapy and stem cell transplant may be required.

Medical Therapy

The predominant therapy for extranodal NK-T-cell lymphoma is radiation therapy. Adjudicative chemotherapy and stem cell transplant may be required.^[1]
Therapy of extranodal NK/T cell lymphoma depends on staging of the tumor:^[2]^[3]^[4]^[5]

Stage	Involvement	Common involvement place	Preferred therapy method	Radiation dosage	Chemotherapy regimen	Alternative therapy	Over 69 /severe organ damage/low lymphocyte
I(E)	Single extranodal involvement	upper aerodigestive tract	Combined modality therapy‡	50 Gy RT	DeVIC∞	40 Gy RT + weekly Cisplatin	-
II(E)	Stage I(E) +One or more of † involvements	upper aerodigestive tract	Combined modality therapy	50 Gy RT	DeVIC	40 Gy RT + weekly Cisplatin	-
III(E)•	Stage I (E) + Cervical lymph node involvement + infra diaphragmatic lymph node / Involvement of spleen	Systemic / Disseminated	SMILE៛	-	-	-	Less intensive L-asparaginase-containing chemotherapy
IV	Stage I(E) +isolated distant involvement	Systemic / Disseminated	SMILE	-	-	-	Less intensive L-asparaginase-containing chemotherapy

†: Cervical lymph node involvement / Involvement of other supradiaphragmatic lymph node regions / Isolated involvement of additional sites in the head and neck

•: Rare

‡: Combined modality therapy is radiation therapy with concurrent chemotherapy

∞: Dexamethasone, Etoposide, Ifosfamide, Carboplatin.

៛: Dexamethasone. Methotrexate, Ifosfamide, L-asparaginase, Etoposide

**Treatment of extranodal NK-T-cell lymphoma^[1]**
Therapy	Description
Radiation therapy	If extranodal NK-T-cell lymphoma is confined to the nose or nasal passages, external beam radiation therapy is used
Chemotherapy	Chemotherapy is often added to radiation therapy to treat extranodal NK/T-cell lymphoma If extranodal NK-T-cell lymphoma is more widespread, then chemotherapy may be more intense and higher doses may be used Drug regimen: (CHOP) Cyclophosphamide AND Doxorubicin AND Vincristine AND Prednisone CNS Prophylaxis: Methotrexate
Stem cell transplant	May be offered to some people with extranodal NK-T-cell lymphoma who relapse after initial treatment

References

↑ ^1.0 ^1.1 Extranodal NK/T-cell lymphoma, nasal type. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/extranodal-nk-t-cell-lymphoma-nasal-type/?region=on. Accessed on February 02, 2016
↑ Dreyling, M.; Thieblemont, C.; Gallamini, A.; Arcaini, L.; Campo, E.; Hermine, O.; Kluin-Nelemans, J. C.; Ladetto, M.; Le Gouill, S.; Iannitto, E.; Pileri, S.; Rodriguez, J.; Schmitz, N.; Wotherspoon, A.; Zinzani, P.; Zucca, E. (2013). "ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma". Annals of Oncology. 24 (4): 857–877. doi:10.1093/annonc/mds643. ISSN 1569-8041.
↑ Isobe, Koichi; Uno, Takashi; Tamaru, Jun-ichi; Kawakami, Hiroyuki; Ueno, Naoyuki; Wakita, Hisashi; Okada, Jun-ichi; Itami, Jun; Ito, Hisao (2006). "Extranodal natural killer/T-cell lymphoma, nasal type". Cancer. 106 (3): 609–615. doi:10.1002/cncr.21656. ISSN 0008-543X.
↑ Li, Ye-Xiong; Yao, Bo; Jin, Jing; Wang, Wei-Hu; Liu, Yue-Ping; Song, Yong-Wen; Wang, Shu-Lian; Liu, Xin-Fan; Zhou, Li-Qiang; He, Xiao-Hui; Lu, Ning; Yu, Zi-Hao (2006). "Radiotherapy As Primary Treatment for Stage IE and IIE Nasal Natural Killer/T-Cell Lymphoma". Journal of Clinical Oncology. 24 (1): 181–189. doi:10.1200/JCO.2005.03.2573. ISSN 0732-183X.
↑ Kim, Seok Jin; Yang, Deok-Hwan; Kim, Jin Seok; Kwak, Jae-Yong; Eom, Hyeon-Seok; Hong, Dae Sik; Won, Jong Ho; Lee, Jae Hoon; Yoon, Dok Hyun; Cho, Jaeho; Nam, Taek-Keun; Lee, Sang-wook; Ahn, Yong Chan; Suh, Cheolwon; Kim, Won Seog (2014). "Concurrent chemoradiotherapy followed by l-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study". Annals of Hematology. 93 (11): 1895–1901. doi:10.1007/s00277-014-2137-6. ISSN 0939-5555.

Template:WikiDoc Sources

[canadiancancer-1] 1.0 ^1.1 Extranodal NK/T-cell lymphoma, nasal type. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/extranodal-nk-t-cell-lymphoma-nasal-type/?region=on. Accessed on February 02, 2016

[DreylingThieblemont2013-2] Dreyling, M.; Thieblemont, C.; Gallamini, A.; Arcaini, L.; Campo, E.; Hermine, O.; Kluin-Nelemans, J. C.; Ladetto, M.; Le Gouill, S.; Iannitto, E.; Pileri, S.; Rodriguez, J.; Schmitz, N.; Wotherspoon, A.; Zinzani, P.; Zucca, E. (2013). "ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma". Annals of Oncology. 24 (4): 857–877. doi:10.1093/annonc/mds643. ISSN 1569-8041.

[IsobeUno2006-3] Isobe, Koichi; Uno, Takashi; Tamaru, Jun-ichi; Kawakami, Hiroyuki; Ueno, Naoyuki; Wakita, Hisashi; Okada, Jun-ichi; Itami, Jun; Ito, Hisao (2006). "Extranodal natural killer/T-cell lymphoma, nasal type". Cancer. 106 (3): 609–615. doi:10.1002/cncr.21656. ISSN 0008-543X.

[LiYao2006-4] Li, Ye-Xiong; Yao, Bo; Jin, Jing; Wang, Wei-Hu; Liu, Yue-Ping; Song, Yong-Wen; Wang, Shu-Lian; Liu, Xin-Fan; Zhou, Li-Qiang; He, Xiao-Hui; Lu, Ning; Yu, Zi-Hao (2006). "Radiotherapy As Primary Treatment for Stage IE and IIE Nasal Natural Killer/T-Cell Lymphoma". Journal of Clinical Oncology. 24 (1): 181–189. doi:10.1200/JCO.2005.03.2573. ISSN 0732-183X.

[KimYang2014-5] Kim, Seok Jin; Yang, Deok-Hwan; Kim, Jin Seok; Kwak, Jae-Yong; Eom, Hyeon-Seok; Hong, Dae Sik; Won, Jong Ho; Lee, Jae Hoon; Yoon, Dok Hyun; Cho, Jaeho; Nam, Taek-Keun; Lee, Sang-wook; Ahn, Yong Chan; Suh, Cheolwon; Kim, Won Seog (2014). "Concurrent chemoradiotherapy followed by l-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study". Annals of Hematology. 93 (11): 1895–1901. doi:10.1007/s00277-014-2137-6. ISSN 0939-5555.

[1]

[2]

[3]

[4]

[5]

@@ Line 19: / Line 19: @@
 ! style="background: #4479BA; color:#FFF;" | Over 69 /severe organ damage/low lymphocyte
 |-
-| style="padding: 5px 5px; background: #DCDCDC"; |I(E)
+| style="padding: 5px 5px; background: #DCDCDC;" align="center" |I(E)
-| style="padding: 5px 5px; background: #F5F5F5;" |Single extranodal involvement
+| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Single extranodal involvement
-| style="padding: 5px 5px; background: #F5F5F5;" |upper aerodigestive tract
+| style="padding: 5px 5px; background: #F5F5F5;" align="center" |upper aerodigestive tract
-| style="padding: 5px 5px; background: #F5F5F5;" |Combined modality therapy‡
+| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Combined modality therapy‡
-| style="padding: 5px 5px; background: #F5F5F5;" |50 Gy RT
+| style="padding: 5px 5px; background: #F5F5F5;" align="center" |50 Gy RT
-| style="padding: 5px 5px; background: #F5F5F5;" |DeVIC∞
+| style="padding: 5px 5px; background: #F5F5F5;" align="center" |DeVIC∞
-| style="padding: 5px 5px; background: #F5F5F5;" |40 Gy RT + weekly Cisplatin
+| style="padding: 5px 5px; background: #F5F5F5;" align="center" |40 Gy RT + weekly Cisplatin
-| style="padding: 5px 5px; background: #F5F5F5;" | -
+| style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
 |-
-| style="padding: 5px 5px; background: #DCDCDC;" |II(E)
+| style="padding: 5px 5px; background: #DCDCDC;" align="center" |II(E)
-| style="padding: 5px 5px; background: #F5F5F5;" |Stage I(E) +One or more of  † involvements
+| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Stage I(E) +One or more of  † involvements
-| style="padding: 5px 5px; background: #F5F5F5;" |upper aerodigestive tract
+| style="padding: 5px 5px; background: #F5F5F5;" align="center" |upper aerodigestive tract
-| style="padding: 5px 5px; background: #F5F5F5;" |Combined modality therapy
+| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Combined modality therapy
-| style="padding: 5px 5px; background: #F5F5F5;" |50 Gy RT
+| style="padding: 5px 5px; background: #F5F5F5;" align="center" |50 Gy RT
-| style="padding: 5px 5px; background: #F5F5F5;" |DeVIC
+| style="padding: 5px 5px; background: #F5F5F5;" align="center" |DeVIC
-| style="padding: 5px 5px; background: #F5F5F5;" |40 Gy RT + weekly Cisplatin
+| style="padding: 5px 5px; background: #F5F5F5;" align="center" |40 Gy RT + weekly Cisplatin
-| style="padding: 5px 5px; background: #F5F5F5;" | -
+| style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
 |-
-| style="padding: 5px 5px; background: #DCDCDC;" |III(E)•
+| style="padding: 5px 5px; background: #DCDCDC;" align="center" |III(E)•
-| style="padding: 5px 5px; background: #F5F5F5;" |Stage I (E) + Cervical lymph node involvement + infra diaphragmatic lymph node / Involvement of spleen
+| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Stage I (E) + Cervical lymph node involvement + infra diaphragmatic lymph node / Involvement of spleen
-| style="padding: 5px 5px; background: #F5F5F5;" |Systemic /
+| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Systemic /
 Disseminated
-| style="padding: 5px 5px; background: #F5F5F5;" |SMILE៛
+| style="padding: 5px 5px; background: #F5F5F5;" align="center" |SMILE៛
-| style="padding: 5px 5px; background: #F5F5F5;" |<nowiki>-</nowiki>
+| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>-</nowiki>
-| style="padding: 5px 5px; background: #F5F5F5;" |<nowiki>-</nowiki>
+| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>-</nowiki>
-| style="padding: 5px 5px; background: #F5F5F5;" |<nowiki>-</nowiki>
+| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>-</nowiki>
-| style="padding: 5px 5px; background: #F5F5F5;" |Less intensive L-asparaginase-containing chemotherapy
+| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Less intensive L-asparaginase-containing chemotherapy
 |-
-| style="padding: 5px 5px; background: #DCDCDC;" |IV
+| style="padding: 5px 5px; background: #DCDCDC;" align="center" |IV
-| style="padding: 5px 5px; background: #F5F5F5;" |Stage I(E) +isolated distant involvement
+| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Stage I(E) +isolated distant involvement
-| style="padding: 5px 5px; background: #F5F5F5;" |Systemic /
+| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Systemic /
 Disseminated
-| style="padding: 5px 5px; background: #F5F5F5;" |SMILE
+| style="padding: 5px 5px; background: #F5F5F5;" align="center" |SMILE
-| style="padding: 5px 5px; background: #F5F5F5;" |<nowiki>-</nowiki>
+| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>-</nowiki>
-| style="padding: 5px 5px; background: #F5F5F5;" |<nowiki>-</nowiki>
+| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>-</nowiki>
-| style="padding: 5px 5px; background: #F5F5F5;" |<nowiki>-</nowiki>
+| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>-</nowiki>
-| style="padding: 5px 5px; background: #F5F5F5;" |Less intensive L-asparaginase-containing chemotherapy
+| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Less intensive L-asparaginase-containing chemotherapy
 |}
 †: Cervical lymph node involvement / Involvement of other supradiaphragmatic lymph node regions / Isolated involvement of additional sites in the head and neck

Extranodal NK-T-cell lymphoma medical therapy: Difference between revisions

Latest revision as of 14:35, 30 August 2019

Overview

Medical Therapy

References

Navigation menu

Search